Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01230502 · ClinicalTrials.gov registry record · NA
Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation
A NA study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- NA
- Development phase
- 11
- Enrollment target
NCT01230502 is a NA study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 11 participants.
The verdict
NCT01230502, a NA study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- NA
- Development phase
- 11 participants
- Enrollment target
Study Summary
To determine whether long-term maintenance therapy with a single drug (Myfortic) applied using advanced immunologic monitoring tools in selected patients can lead to superior native kidney function at 2 years without resulting in increased acute rejection episodes or deterioration of liver allograft function.
Interventions
- DRUG Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy
- OTHER data and sample collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01230502
The ClinicalTrials.gov registry entry for NCT01230502 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy is the first listed.
NCT01230502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01230502 about?
NCT01230502 is a clinical study titled "Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation". To determine whether long-term maintenance therapy with a single drug (Myfortic) applied using advanced immunologic monitoring tools in selected patients can lead to superior native kidney function at 2 years without resulting in increased acute rejection episodes or deterioration of liver allograft...
What is the current status of trial NCT01230502?
This trial is currently terminated. It is a NA study. The enrollment target is 11 participants. The study started on 2011-11. Estimated completion is 2012-06.
What interventions are being tested in trial NCT01230502?
The interventions under investigation include: Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy (DRUG), data and sample collection (OTHER).
Who is sponsoring clinical trial NCT01230502?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.